A CRO FOR PRECLINICAL SERVICES IN ONCOLOGY

Antineo

About Us

Spin-off of the Team Anticancer Antibodies
Centre de Recherche en Cancérologie (CRCL)

Company

CRO created in May 2015, specialized in proof-of-concept studies in oncology

Team

Scientists and efficient team recognized for its expertise in onco-pharmacology at the international level

Location

Hôpital Edouard Herriot
Lyon, France

Customers

French and international clients composed of pharmaceutical, biotechnology companies and academic institutions

Regulation

- CIR agreement 2020-2023
- Fully authorized animal house and personnel

Track-record

- 100+ studies
- 40 sponsors
- 5 ongoing partnerships

Antineo

OUR TEAM

Charles Dumontet, MD-PhD
Scientific Consultant

Marie Tautou, PhD
Study Director & Head of Business Development

Charline Perrouin
Business Development Manager

Doriane Mathé
Study Manager

Pierre-Antoine Choffour
Study Manager

Marine Fellmann
Study Manager

Mélina Gauthier
Study Assistant

Jade Ruard
Study Assistant

Stecy Chhor
Study Assistant

Antineo

THERAPEUTIC AREAS

Oncology and immuno-oncology

Small molecules



Biological molecules

Antibodies, peptides

Cellular and gene therapies



Antineo

OUR SERVICES

Antineo's services

Optimize and accelerate the development of our customers' compounds

Provide advices, expertise and services



Antineo

IN-VITRO SERVICES

Cytotoxicity assays

Determination of IC50 / EC50

Synergy / Antagonism assay

Colorimetric method

Luminescence method

MTT

MTS

Cell Titer-Glo®





Cell viability / Cell metabolic activity / Cytotoxicity / Cell proliferation



Continuous-monitoring studies

Realize a real-time analysis of a variety of cellular and immunological processes



Characterisation of samples



Quantitative PCR

Western Blotting

ELISA assays

Immunoprecipitation

Flow cytometry studies

Flow Cytometry - (FACS)

Qualitative and quantitative multiparametric analyses

LSR FORTESSA™	VS	CYTEK
Classical	≠	Spectral
3 panels : 12, 16, 20 markers		4 panels : 16, 18, 22, 29 markers





Antineo

EX-VIVO SERVICES

Immunology services

Isolate the cells of interest and characterise your target molecule by Flow Cytometry

- **Analysis on fresh samples** : on blood products (blood bags) and by products (buffy coat)
- Most assays can be performed as **end point** and **continuous-monitoring** studies

T cell based assays

Myeloid Cells based assays

ADCC assays with fresh NK cells

ADCP assays with fresh myeloid cells

Development of immunotherapies

Highlight the target and decipher the mechanisms of action of therapeutic antibodies

- **Immunology ex vivo assays** (T cell activation by IFNγ measurements, CTL assays, Macrophage polarisation etc.)
- In vitro or ex vivo **ADCC, ADCP and CDC assays** (calcein release)
- Original methods for **in vivo assessment of ADCC and CDC activities**
- Original in vitro and in vivo assays for **bispecific antibodies** (anti-CD3)
- A unique panel of tumour models presenting **secondary resistances to immunotherapies**



IN-VIVO SERVICES

Choice of tumor models

- 100+ cell-derived xenograft models
- 40 murine syngeneic models for immuno-oncology
- Subcutaneous or orthotopic implantation

Standard of care therapies

- As reference for the tested compound
- For comparison studies
- For combinaison / synergy studies

Protocol adapted to our clients' compounds

- Route (IV / IP / PO)
- Galenic formulations (liposome encapsulation)
- Schedule of injection
- Schedule and duration of follow-up
- Weekly updates
- Choice of end-point (with control or individual ethical end-points)



In-vivo analysis

Demonstrate the antitumor activity of a novel agent in animal models, as well as defining the dosage and schedule that is both efficient and non-toxic

- Recommendations on the choice of the best indication and model
- Systemic and haematological toxicity of your compounds in rodents (VetScan / MS9)
- Pharmacokinetics properties in mouse and rat
- Antitumor efficacy in human or mice tumour models
- Combination / comparison with gold standards

- Orthotopic models*
- Immunophenotyping of the tumour micro environment
- An original offer of secondary resistances to reference therapies (CDX and syngeneic)
- The development of models of resistance

* *Denis, M. (2021). Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy*



ORIGINAL RESISTANT TUMOR MODELS

CDX Models

Lymphoma

- Follicular Lymphoma - (RL model *: Rituximab / GA101 / R-CHOP / R-DHAP)*
- Mantle Cells Lymphoma - (Granta model : *Rituximab*)
- Diffuse large B cells lymphoma - (Toledo model : *Rituximab*)
- Burkitt's lymphoma - (Raji model : *Rituximab*) / Daudi model : *cal101*)

Myeloma

Plasma cells myeloma
RPMI8226 model
- *Daratumumab*

Breast

Tubular Adenocarcinoma
BT474
- *T-DM1*

MDA-MB-361 model
- *Trastuzumab T-DM1*

Colorectal / Gastric

Gastric carcinoma
NCI-N87
- Trastuzumab



Bespoke services : *On demand development of resistant models (Syngeneic or CDX models)*

Syngeneic Models

Colon

MC38 model
- *anti-PD1 / anti-PDL-1*

Bladder

MBT-2 model
- *anti-PD1*

MB49 model
- *anti-PD1 / anti-PDL-1*

Kidney

RENCA model
- *anti-PD1 / anti-PDL-1*

Melanoma

B-raf
- *anti-PD1 / anti-PDL-1*

N-Ras
- *anti-PD1 / anti-PDL-1*

Tyr N-Ras models
- *anti-PD1 / anti-PDL-1*

BRAND NEW : Pancreas

Kic8 model
- *PD1 / PDL1 / Gemcitabine*

Lymphoma

P388 model
- *anti-PD1 / anti-PDL-1*

CDX Models

Lymphoma

- Follicular Lymphoma - (RL model : *Rituximab / GA101 / R-CHOP / R-DHAP)*
- Mantle Cells Lymphoma - (Granta model : *Rituximab*)
- Diffuse large B cells lymphoma - (Toledo model : *Rituximab*)
- Burkitt's lymphoma - (Raji model : *Rituximab*) / Daudi model : *cal101*)

Myeloma

Plasma cells myeloma
RPMI8226 model
- *Daratumumab*

Breast

Tubular Adenocarcinoma
BT474
- *T-DM1*

MDA-MB-361 model
- *Trastuzumab T-DM1*

Colorectal / Gastric

Gastric carcinoma
NCI-N87
- Trastuzumab

Bespoke services : *On demand development of resistant models (Syngeneic or CDX models)*

Syngeneic Models

Colon

MC38 model
- *anti-PD1 / anti-PDL-1*

Bladder

MBT-2 model
- *anti-PD1*

MB49 model
- *anti-PD1 / anti-PDL-1*

Kidney

RENCA model
- *anti-PD1 / anti-PDL-1*

Melanoma

B-raf
- *anti-PD1 / anti-PDL-1*

N-Ras
- *anti-PD1 / anti-PDL-1*

Tyr N-Ras models
- *anti-PD1 / anti-PDL-1*

BRAND NEW : Pancreas

Kic8 model
- *PD1 / PDL1 / Gemcitabine*

Lymphoma

P388 model
- *anti-PD1 / anti-PDL-1*



Acquired resistance to anti-PD(L)1



Our established resistance models



** Denis, M. (2021). Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy*

Partner platforms

CIQLE

Microscopy platform for Immunohistochemistry **(IHC)**

IMTHERNAT

PET-Scan (Radiolabelling)

PROFIL EXPERT

High throughput sequencing, microdissection and single cell technologies

HAWKCELL

Platform for Magnetic Resonance Imaging (MRI)

ANAQUANT

Detection and quantification of proteins by mass spectrometry

Antineo

OUR NEWS

Imageur - IVIS® Lumina Series III

MDA-MB-231 cell line



15/03/2023



23/03/2023



30/03/2023

- **In vivo and 3D imaging** of the tumors/metastasis
- **Precise tumor monitoring and follow-up**
- **Animal saving**

Hepatic metastases of an MDA-MB-231 Luciferase (+) model by intrasplenic implantation

Antineo

CASE STUDIES

Efficiency study







Toxicity study – Haematological analysis







mAb Titration assay (SK-BR3)



mAb Internalization assay (SK-BR3)



Antineo

THEY TRUST US!


advanced
biodesign


CRCL
CENTRE DE
RECHERCHE EN
CANCÉROLOGIE
DE LYON


DIACCURATE


Roche


imescia


Jalon
THERAPEUTICS


GAMA MABS
PHARMA

THANK YOU!

(+33) 4 72 36 15 71

www.antineo.fr

Hôpital Edouard Herriot, 5 place d'Arsonval - 69437 LYON

Antineo